Abstract

ICU Medical will report first-quarter 2026 results on May 7, 2026 Post Market; consensus points to lower revenue year over year but stronger profitability metrics, setting the stage for an earnings mix driven more by margin progress than top-line acceleration.

Market Forecast

For the first quarter of 2026, the market’s consensus expects ICU Medical to deliver revenue of 520.48 million US dollars, down 8.71% year over year, EBIT of 77.75 million US dollars, up 15.53% year over year, and adjusted EPS of 1.75, up 36.85% year over year; margin forecasts are not formally published, but the prior quarter’s 37.54% gross margin provides the baseline reference. Within the product mix, infusion disposables remain the anchor at roughly half of sales; if mix holds, this implies about 258.72 million US dollars in first-quarter revenue for disposables and reinforces the margin-led narrative as the key watch item.

Last Quarter Review

In the prior quarter, ICU Medical reported revenue of 535.94 million US dollars, a gross profit margin of 37.54%, GAAP net loss attributable to shareholders of 15.73 million US dollars, a net profit margin of -2.91%, and adjusted EPS of 1.91, reflecting a 13.78% year-over-year decline in revenue and a 9.48% year-over-year decline in adjusted EPS; quarter-on-quarter, GAAP net profit contracted sharply as indicated by a -363.31% swing in net profit change. A key financial highlight was the divergence between GAAP and adjusted performance: despite a GAAP net loss, operating profitability remained intact with EBIT at 82.89 million US dollars, indicating that non-operational or non-recurring items masked underlying margin resilience. Main business highlights show a balanced revenue structure that helps stabilize cash generation: using last quarter’s mix, infusion disposables contributed about 266.41 million US dollars, infusion systems about 164.34 million US dollars, and critical care about 105.19 million US dollars, against an overall company revenue decline of 13.78% year over year.

Current Quarter Outlook

Main business: Infusion disposables

Infusion disposables comprise roughly half of ICU Medical’s revenue base and anchor gross margin quality. With first-quarter revenue projected at 520.48 million US dollars and mix assumed to be stable, disposables would represent approximately 258.72 million US dollars. The disposables line is closely tied to realized pricing, material costs, and logistics. Even with a projected year-over-year revenue decline at the company level, consensus expects notable earnings leverage, signaling that disposables should sustain, if not slightly improve, unit economics through cost discipline and manufacturing efficiencies. Any incremental relief in resin, packaging, or freight inputs can translate into higher contribution margins and support EBIT outperformance. Conversely, rebates or mix shifts within the disposables portfolio can modestly cap upside if the higher-volume SKUs carry tighter pricing bands. Monitoring the gross margin path relative to last quarter’s 37.54% will be critical to interpreting whether disposables continue to provide the intended protection for earnings quality. On balance, disposables appear positioned to deliver consistent flow-through and form the backbone of the anticipated EPS growth despite a softer top line.

Largest near-term upside candidate: Infusion systems

Infusion systems is the second-largest revenue contributor and a logical candidate for incremental upside if execution on backlog conversion and service attach rates remains steady. Using the prior quarter’s mix as a guide, systems would imply about 159.60 million US dollars on the current-quarter revenue consensus. This business line amplifies operating leverage when volumes are stable, because absorption and field utilization can lift margin density faster than headline revenue growth. The current set of expectations—revenue down 8.71% year over year but EBIT up 15.53%—implicitly assumes a margin lift that is consistent with tighter cost control across manufacturing, field support, and post-acquisition integration synergies. If management’s cost actions continue to reduce conversion costs and installation bottlenecks, systems can outperform consensus EBIT even if revenue is simply in line. The flipside is sensitivity to delivery timing and customer scheduling, which can push revenue recognition between quarters; this can add volatility to near-term prints without altering the medium-term earnings path. For this quarter, systems execution—particularly timely conversions and mix within the installed base—could be the lever that determines whether EPS comes in above the 1.75 consensus.

Stock-price swing factor: Margin trajectory and earnings mix

Consensus embeds a constructive margin narrative: EBIT estimated at 77.75 million US dollars, up 15.53% year over year, and adjusted EPS at 1.75, up 36.85% year over year, despite revenue down 8.71% year over year. That profile will focus investor attention less on headline sales and more on gross margin resilience, conversion costs, and operating expense containment. A 100-basis-point change in gross margin on 520.48 million US dollars of revenue equates to roughly 5.20 million US dollars of gross profit; depending on operating expense absorption, the incremental EBIT flow-through can be meaningful relative to the 77.75 million US dollars baseline. If realized margins print above the 37.54% prior-quarter level, the earnings mix should skew favorably and help offset top-line softness. Conversely, if gross margin dips below that reference point due to price or mix pressure, the EPS algorithm will tighten and could place the quarter at risk versus consensus. Management’s commentary on cost normalization, efficiency initiatives, and cash conversion will be a high-impact variable for post-print trading because it provides forward confidence on whether EBIT expansion is sustainable.

Cash discipline and deleveraging lens

The divergence between GAAP loss and adjusted profitability in the last quarter highlights the importance of cash measures this period. Investors will parse working-capital movements—inventory turns and receivables—given their influence on free cash flow and on the company’s capacity to reinvest while managing leverage. With EBIT expected to grow year over year, the market will look for evidence that operating cash aligns with earnings improvements, suggesting that the margin gains are not being diluted by temporary working-capital swings. Any commentary on capital spending cadence, inventory normalization, and supplier terms could sharpen estimates for full-year free cash flow, which is an important input into equity valuation and can modulate how investors discount near-term revenue softness. If the company demonstrates tighter cash conversion and provides clarity on debt metrics, this would reinforce the bullish interpretation of an EPS-led recovery profile. In contrast, signs of inventory build or elongated receivables could lessen the perceived quality of earnings and temper the stock’s reaction even if headline EPS is in line.

Guidance framework and read-through to the rest of 2026

A central question for this print is how management frames the balance of the year as margins improve while revenue comps remain challenging. If guidance reiterates that cost actions and productivity will continue to outweigh volume pressure, the market is likely to extrapolate a steadier path for EBIT and EPS. This would be consistent with the current quarter’s estimates, where the expected earnings outperformance relies more on margin than on top-line acceleration. Specifics on procurement savings, manufacturing yields, and any residual integration benefits can help quantify the durability of the EBIT trajectory. Should management flag renewed investment in product refreshes or support infrastructure, investors may accept near-term expense upticks if accompanied by credible timelines for payback. Conversely, any indication that pricing or mix is eroding faster than cost reductions could prompt a reset of the earnings cadence for the year, which would weigh on sentiment. The tone and structure of commentary on costs, pricing, and throughput will therefore be pivotal for how the stock trades post-report.

What to watch in the print

- Gross margin relative to the 37.54% prior-quarter level, as a direct signal of cost normalization and mix. - EBIT margin progression implied by the 77.75 million US dollars EBIT estimate, given revenue softness. - Segment performance consistency versus last quarter’s mix: approximately 49.71% disposables, 30.66% systems, and 19.63% critical care by revenue share. - Adjusted EPS execution relative to the 1.75 consensus, since expectations imply expanding conversion of gross profit into earnings. - Cash conversion and working-capital trends to validate that earnings growth is backed by operational cash flows.

Analyst Opinions

Across the limited set of published previews and recent commentary within the defined period, the balance of views tilts bullish, with identified opinions skewing 100% constructive versus 0% cautious. The prevailing interpretation is that consensus numbers—revenue down 8.71% year over year to 520.48 million US dollars with EBIT up 15.53% and adjusted EPS up 36.85%—reflect an earnings mix that can improve even in a softer revenue environment. This has framed expectations around margin resilience and cost execution as the dominant drivers for the quarter. Recent results have also been read positively by market commentators, noting that the most recent quarter’s adjusted EPS of 1.91 and sales of 535.94 million US dollars exceeded commonly tracked estimates, which reinforces the case for a margin-led path in the near term. The bullish stance argues that continued control of conversion costs, supply logistics, and expense discipline can sustain double-digit EBIT growth, providing a cushion against volume variability and positioning earnings to outperform consensus if execution is clean. From this vantage point, the key debate is not whether revenue will compress year over year—consensus already embeds that—but whether gross margin and operating leverage can again offset the top-line pressure. Supporters expect that incremental savings and a steadier cost base can preserve or expand margins versus the 37.54% reference point, enabling EPS to meet or beat the 1.75 bar. They also point to the implied mix stability—approximately half in disposables—favoring predictability in contribution margins. In sum, the majority view anticipates that ICU Medical’s first quarter will validate the thesis that earnings quality is improving ahead of sales, with the post-report stock reaction most sensitive to the gross margin line and management’s commentary on the sustainability of cost and productivity gains.